#Olomorasib
LightNews LightNews
biologist077.bsky.social
Wish more people knew about this. FDA gave "Breakthrough" status to olomorasib for KRAS G12C pancreatic cancer, a super aggressive type where 5-yr survival for metastatic cases is under 5%. Early Phase 1/2 data showed ALL evaluable patients had tumor volume decrease.
August 5, 2026 at 2:04 PM
jyves94.bsky.social
L’ #Olomorasib associé au #Pembrolizumab obtient la désignation de "traitement révolutionnaire" dans le traitement du #CPNPC avec mutation #KRAS #G12C non traité.

Les résultats seront présentés lors de la Conférence mondiale sur le #CancerDuPoumon 2025 de l’ #IASLC ( #WCLC2025).
September 4, 2025 at 7:50 PM
jyves94.bsky.social
🚨 La #FDA a accordé la désignation de "thérapie révolutionnaire" à l’ #Olomorasib + #Pembrolizumab pour le #CancerDuPoumon ( #CPNPC)
🧬 Les 1ères données de l’essai LOXO-RAS-20001 montrent que :
✅ ORR : 74 %
✅ TCD : 91 %
✅ Des réponses durables

Plus d'info à #WCLC2025
www.onclive.com/view/olomora...
Olomorasib Plus Pembrolizumab Earns Breakthrough Therapy Designation in Untreated KRAS G12C–Mutated NSCLC
Olomorasib plus pembrolizumab has been granted breakthrough therapy designation by the FDA in first-line KRAS G12C–mutated NSCLC.
www.onclive.com
September 4, 2025 at 7:42 PM
l2plabs.bsky.social
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers
The Breakthrough Therapy designation for olomorasib is based on data from the Phase 1/2 LOXO-RAS-20001 trial and Phase 3 SUNRAY-01 trial Updated efficacy and safety data for olomorasib will be presented at the IASLC 2025 World Conference on Lung Cancer INDIANAPOLIS, Sept. 4, 2025...
dlvr.it
September 4, 2025 at 10:47 AM
1technodiva.bsky.social
My son-in-law's dad started this last week. Praying it gives him time to see his only daughter married 🤲 Grateful for any drugs that make it past the brain-worm feeding bin.

investor.lilly.com/news-release...
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer | Eli Lilly and Company
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
investor.lilly.com
August 6, 2026 at 4:33 PM
cancertherapyadv.bsky.social
Abstract 3507 (bit.ly/4mAT5vz). The combination of olomorasib and cetuximab demonstrated activity in this phase 1/2 study of patients with KRAS G12C-mutant colorectal cancer. #ASCO25 #gicsm
Program Guide – ASCO Meeting Program Guide
bit.ly
May 29, 2025 at 1:40 PM
tangusmac1.bsky.social
investor.lilly.com/news-release...
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer | Eli Lilly and Company
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
investor.lilly.com
August 4, 2026 at 2:02 AM
thebiotechtimes.bsky.social
Amplia and Lilly are dosing a Phase 1b/2b combo trial of narmafotinib and olomorasib in KRAS G12C NSCLC, launching late 2026. Targeting resistance pathways.
Amplia signs Lilly deal to test FAK inhibitor in KRAS G12C lung cancer
Amplia Therapeutics will combine narmafotinib with Lilly's olomorasib in a Phase 1b/2b NSCLC trial starting late 2026, targeting KRAS G12C resistance.
biotech.disruptsmedia.com
August 22, 2026 at 2:00 PM
corterve.bsky.social
Breaking: Eli Lilly's olomorasib gets FDA Breakthrough Therapy designation for advanced pancreatic cancer (Aug 8). Second breakthrough nod for this KRAS G12C inhibitor. Also entering a new combo trial with Amplia's narmafotinib in NSCLC. #ClinicalTrials #PancreaticCancer

corterve.com/trials
August 11, 2026 at 11:02 AM
borsatek.bsky.social
Eli Lilly’nin kanser ilacı olomorasib FDA’den kritik onay aldı #EliLilly #FDA #KRASG12C
Eli Lilly’nin kanser ilacı olomorasib FDA’den kritik onay aldı
Eli Lilly'nin geliştirdiği KRAS G12C inhibitörü olomorasib, ilerlemiş pankreas kanseri endikasyonunda FDA'den Atılım Terapisi statüsü kazandı.
dlvr.it
August 8, 2026 at 11:01 PM
corterve.bsky.social
FDA grants Breakthrough Therapy to Lilly's olomorasib for KRAS G12C-mutant pancreatic cancer. A selective oral KRAS G12C inhibitor based on promising Phase 1/2 data. Second BTD for olomorasib — also designated for KRAS G12C NSCLC with Keytruda.

#PancreaticCancer #ClinicalTrials
August 6, 2026 at 11:19 AM
medchemexpress.bsky.social
🔬What's next?
🔹 SUNRAY-01 (Phase 3): Olomorasib + pembrolizumab ± chemotherapy in advanced #NSCLC
🔹 SUNRAY-02 (Phase 3): Evaluating olomorasib with standard immunotherapy in resected or unresectable disease
August 5, 2026 at 3:00 PM
medchemexpress.bsky.social
🚀The #FDA has granted Breakthrough Therapy Designation to #olomorasib for adults with previously treated, KRAS G12C-mutant advanced pancreatic cancer

🔸 Olomorasib is a next-generation KRAS G12C inhibitor designed to achieve sustained target inhibition with a favorable safety profile.
August 5, 2026 at 3:00 PM
biostock.bsky.social
🟢 #$LLY — Regulatory Designation
FDA Breakthrough Therapy Designation - Olomorasib in KRAS G12C-Mutant Pancreatic Cancer
FDA granted Breakthrough Therapy designation to olomorasib for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cance…

https://biostock.app/symbols/LLY
August 5, 2026 at 1:33 PM
corterve.bsky.social
FDA grants Breakthrough Therapy designation to Lilly's olomorasib for KRAS G12C-mutant pancreatic cancer (Aug 3). Trial NCT04956640 is enrolling KRAS G12C solid tumors. KRAS mutations occur in ~40% of colorectal cancers.

corterve.com/trials #ClinicalTrials #CancerResearch
August 5, 2026 at 5:09 PM
medchemexpress.bsky.social
📊LOXO-RAS-20001:
🔹74% ORR and 91% DCR in first-line KRAS G12C-mutant #NSCLC when combined with #pembrolizumab
🔹90% ORR in patients with PD-L1 ≥50%
These findings support the potential of combining next-generation KRAS G12C inhibition with immunotherapy to improve outcomes in advanced lung cancer
FDA Grants Breakthrough Therapy Designation to Olomorasib in KRAS G12C+ Pancreatic Cancer | OncLive
Olomorasib earned breakthrough therapy status as a monotherapy for adults with previously treated, KRAS G12C-mutant advanced pancreatic cancer.
www.onclive.com
August 5, 2026 at 3:00 PM
douglaswalton999.bsky.social
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer share.google/nXrbTGV4zPl4...

Good news
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation...
share.google
August 5, 2026 at 6:27 AM
ampliaceo.bsky.social
Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer
#pancreaticcancer #FAK #olomorasib #narmafotinib
www.globenewswire.com/news-release...
Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer
HIGHLIGHTS Amplia has executed a Clinical Trial Collaboration & Supply Agreement (CTCSA) with Eli Lilly & Company, to evaluate the Company’s...
www.globenewswire.com
August 4, 2026 at 9:20 PM
cafepharma.bsky.social
Tue news: Pfizer tops estimates, hikes low end of revenue guidance. FDA grants breakthrough therapy designation to Lilly’s olomorasib. As portfolio erodes, BMS stands to gain a lot from rumored AZ merger. Merck beats on revenue but slashes forecast. —https://bit.ly/3JeBlY5
August 4, 2026 at 3:57 PM
yieldgraphbeleggen.bsky.social
Eli Lilly krijgt FDA-erkenning voor kankerbehandeling olomorasib

De FDA verleende Breakthrough Therapy-status aan Eli Lilly's olomor…

https://yieldgraph.nl/blog/eli-lilly-krijgt-fda-erkenning-voor-kankerbehandeling-olomorasib/ #financien #aandelen #beurs #beursnieuws #lly #WallStreet #YieldGraph
August 4, 2026 at 4:00 AM
wsnext.com
Eli Lilly Drug Earns Fast-Track FDA Status for Pancreatic Cancer

https://wsnext.com/3aa0e1c-Eli-Lilly-Oncology-Drugs/
Eli Lilly Drug Earns Fast-Track FDA Status for Pancreatic Cancer
Indianapolis, Tuesday, 4 August 2026.Eli Lilly received FDA Breakthrough Therapy designation for olomorasib to treat advanced pancreatic cancer. This marks the drug’s second fast-track status, address
wsnext.com
August 4, 2026 at 4:28 AM
newsen.bsky.social
Eli Lilly Achieves Breakthrough Therapy Status for Olomorasib Treatment in Advanced Pancreatic Cancer#United_States#Indianapolis#Eli_Lilly#KRAS_G12C#Olomorasib
Eli Lilly Achieves Breakthrough Therapy Status for Olomorasib Treatment in Advanced Pancreatic Cancer
Eli Lilly's olomorasib has garnered Breakthrough Therapy designation from the FDA for treating KRAS G12C-mutant advanced pancreatic cancer, highlighting new treatment opportunities.
third-news.com
August 3, 2026 at 11:53 AM
onclive.bsky.social
💥 @fda.gov has granted a breakthrough therapy designation to olomorasib in KRAS G12C-mutated pancreatic cancer, based on data from the phase 1/2 LOXO-RAS-20001 trial.

Read here 📈: www.onclive.com/view/olomora...

#pancsm #oncology
FDA Grants Breakthrough Therapy Designation to Olomorasib in KRAS G12C+ Pancreatic Cancer | OncLive
Olomorasib earned breakthrough therapy status as a monotherapy for adults with previously treated, KRAS G12C-mutant advanced pancreatic cancer.
www.onclive.com
August 3, 2026 at 3:14 PM
douglaswalton999.bsky.social
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer | Eli Lilly and Company share.google/j2PIRhIfdBO6...
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer | Eli Lilly and Company
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
share.google
August 3, 2026 at 2:08 PM
blueresearch.bsky.social
Eli Lilly says FDA grants Breakthrough Therapy designation to olomorasib
Reported Monday, Aug 3 - 7:46am EDT (TheFly subscription required to read more.)
thefly.com
August 3, 2026 at 11:50 AM